The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American descent, poor ECOG performance status, and chronic viral infections.
 
Neil J. Shah
Honoraria - Castle Biosciences; Castle Biosciences
 
Matthew Blackburn
No Relationships to Disclose
 
Michael R Cook
No Relationships to Disclose
 
Anas Belouali
No Relationships to Disclose
 
Michael Serzan
No Relationships to Disclose
 
William Kelly
No Relationships to Disclose
 
Athanasios Bikas
No Relationships to Disclose
 
Chul Kim
Research Funding - AstraZeneca; Novartis
Travel, Accommodations, Expenses - Caris Life Sciences
 
Subha Madhavan
Leadership - Perthera
Stock and Other Ownership Interests - Perthera
Consulting or Advisory Role - Perthera
Research Funding - Teewinot Life Sciences (Inst)
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; HERON; Lilly; Pfizer; Regeneron; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Bayer; Blueprint Medicines; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Lilly; Lycera; Merck; Molecular Partners; OncoMed; Pfizer; Threshold Pharmaceuticals
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Merck; Newlink Genetics/Pharmatech; Novartis; Oncolys BioPharma; Pfizer; Surface Oncology; Werewolf Pharma; X4 Pharma
Research Funding - Bristol-Myers Squibb (Inst)